focus -WSS

focus

author：hotspot 2025-09-27 21:54:56 - browse：5

Business standing in the middle of a maze near a bag with a dollar sign on it. -- biotech coverage from STAT — Adobe

Over the last year or two, something curious has started occurring in the conference rooms and private Zoom meetings of biotech venture capitalists.

Representatives from pension funds, college endowments, family offices, and other organizations with money to invest have become bolder in their requests, according to interviews with a host of VCs. They’re pushing not only for advantageous terms in a VC firm’s latest fund, but in some cases, have angled for equity in the firm itself. These types of conditions aren’t unheard of, but have become more frequent as venture capitalists have a harder time raising funds, and as outside investors feel empowered to ask for more bang for their buck.

“A lot is changing in venture fundraising right now,” said Nan Li, co-founder and managing partner of Dimension, which launched last January. Outside investors tried to ask for a piece of Dimension, but the new firm had more than enough interest in its first fund and was able to turn down those proposals. Two other young VC firms told STAT they’ve fielded similar requests, and one investment group reported that it had managed to negotiate an equity stake in a VC firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： The Harvard botanist who searched for psychedelics in the Amazon

WSS

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

PBM reform efforts get punted in Congress

Trans patients at the end of life deserve respect and dignity

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Intellia plays down concerns on accidental germline transmission

focus

focus

knowledge

Cancer drug shortages should be causing more outrage

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

The cancer drug shortage isn’t new — and neither are the solutions

Community Health Systems hospitals under DOJ investigation

Psychedelics group wrestles with new pharma identity

In utero gene editing: an explainer

New air purifier tech could be key to improving indoor air quality

Roche's accidental data boosts hopes for anti

Activists slam private health insurers over coverage restrictions

Abortion policy in the spotlight at Republican debate

knowledge

R1 RCM gets $5.8 billion buyout offer from private equity firm

STAT readers on older presidents, polypills, Medicare, and more

How the drug

Roche's accidental data boosts hopes for anti

Vivek Ramaswamy made waves in the debate, much as in biotech

Meadows told special counsel he could not recall Trump ever declassifying Mar

knowledge

Wikipedia

hotspot

hotspot